drugset
drugset / Trial / NCT01330966

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

NCT01330966 ↗

Phase 2 Completed 47 enrolled Emerald Clinical Inc. GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.

Timeline

Start
2011-04
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 800 mg Oral

Indications

chondrosarcoma